The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by excessive hepatic fat accumulation. Intermittent fasting (IF) has emerged as a potential therapeutic strategy with the ability to induce weight loss, improve insulin sensitivity and reduce hepatic steatosis. We aim to compare the efficacy of different IF regimens for MASLD management. A systematic review and network meta-analysis of randomized controlled trials investigating different IF regimens for MASLD. PubMed, EMBASE, WOS, SCOPUS and Cochrane Central Register of Controlled Trials were searched until 10 April 2023. Analysis was performed using R software with the meta and netmeta packages. Mean difference (MD) was used to pool continuous outcomes with 95% confidence intervals (CIs). Our meta-analysis was registered in PROSPERO (CRD42023418467). Our meta-analysis included eight randomized controlled trials with a total of 635 participants. The 5 : 2 diet significantly improved liver stiffness (MD, −0.32; 95% CI, −0.55 to −0.09; P < 0.01). Time-restricted feeding significantly improved liver steatosis (controlled attenuation parameter score) (MD, −39.83; 95% CI, −64.78 to −14.87; P < 0.01). No significant changes were observed in asparate aminotransferase, gamma-glutamyl transpeptidase, low-density lipoproteins cholesterol, total cholesterol, triglyceride levels, basal metabolic index, blood pressure, Homeostatic Model Assessment of Insulin Resistance, fasting blood sugar, lean body mass or waist circumference across all IF regimens. However, alternate-day fasting showed positive results in anthropometric measures, including significant improvements in lean body mass, waist circumference, fat mass and weight reduction (P < 0.05). IF regimens showed various positive effects on clinical outcomes in MASLD patients; however, these effects were not consistent. Therefore, a patient-tailored IF regimen should be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, no significant differences were observed between IF and CER for other metabolic or hepatic biochemical markers, suggesting that short-term metabolic improvements may be comparable between the two regimens (17, 29).”
From Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis (2026) · cites this paper as [17]
In the citing paper
“Intermittent fasting (IF) and continuous energy restriction (CER) are widely used dietary approaches for metabolic dysfunction–associated steatotic liver disease (MASLD), yet their comparative efficacy remains uncertain.”
From Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis (2026) · cites this paper as [17]
In the citing paper
“In addition, a recent systematic review and network meta-analysis suggested that intermittent fasting regimens may improve hepatic and metabolic outcomes in MASLD, although the comparative efficacy across fasting regimens and against CER remains uncertain (17).”
From Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis (2026) · cites this paper as [17]
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“The risk of bias in the included RCTs was evaluated through the use of the Cochrane Collaboration’s updated RoB 2 tool [17].”
MethodCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“…and network meta-analysis were carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, Supplemental digital content 1, http://links. lww.com/EJGH/A989 ) guidelines [15]. and the Cochrane Handbook of Systematic Reviews and Meta-analysis [16].”
MethodYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 1×
“Evidence shows that MASLD is strongly associated with obesity, insulin resistance and other components of the metabolic syndrome, such as hypertension, type II diabetes and dyslipidemia [2–6].”
BackgroundCochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476 · cited 2×
“…beginning with a simple fatty liver showing no symptoms of nonalcoholic steatohepatitis, also replaced by the new term metabolic dysfunction-associated steatohepatitis [1], progressing to cirrhosis, and hepatocellular carcinoma if untreated, constituting a significant public health concern [7].”
BackgroundZelber–Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., Leshno, M., Blendis, L., Halpern, Z., & Oren, R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.004 · Cited by 317
Obesity and nonalcoholic fatty liver disease: current perspectives
Sarwar, R., Pierce, N., & Koppe, S. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s146339 · Cited by 232
Holmer, M., Lindqvist, C., Petersson, S., Moshtaghi-Svensson, J., Tillander, V., Brismar, T. B., Hagström, H., & Stål, P. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100256 · Cited by 224
Cai, H., Qin, Y.-L., Shi, Z.-Y., Chen, J.-H., Zeng, M.-J., Zhou, W., Chen, R.-Q., & Chen, Z.-Y. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1132-8 · Cited by 205
Cited by
Simancas-Racines, D., Annunziata, G., Verde, L., Fascì-Spurio, F., Reytor-González, C., Muscogiuri, G., Frias-Toral, E., & Barrea, L. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00597-6 · Cited by 61
Hamamah, S., Iatcu, O. C., & Covașă, M. (2024) · Nutrients · doi:10.3390/nu17010143 · Cited by 56
Wang, Y.-Y., Tian, F., Qian, X.-L., Ying, H.-M., & Zhou, Z.-F. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1439473 · Cited by 28
Giannakogeorgou, A., Roden, M., & Pafili, K. (2025) · HORMONES · doi:10.1007/s42000-025-00701-y · Cited by 24
Palumbo, P., Betto, G. D., Menozzi, R., Koek, G. H., & Buzzetti, E. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156425 · Cited by 22
Metadata
- Authors
- Abuelazm, M. T., Mohamed, I., Naeem, A., Khlidj, Y., Tanashat, M., Katamesh, B. E., Abusuilik, H., Altobaishat, O., Abdelnabi, M., & Abdelazeem, B.
- Affiliations
- Tanta University (EG)
- University of Missouri (US)
- Al-Azhar University (EG)
- Faculty of Medicine, University of Algiers, Algiers, Algeria
- Yarmouk University (JO)
- Mayo Clinic (US)
- Faculty of Medicine, Hashemite University, Zarqa, Jordan
- Jordan University of Science and Technology (JO)
- University of Michigan (US)
- West Virginia University (US)
- Corresponding author
- Abuelazm, Mohamed T.
- Mohamed, Islam
- ORCID
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2024-02-23
- Volume
- 36
- Issue
- 4
- Pages
- 371-381
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W4392166828
- Cited by
- 21
- References
- 35
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 4
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- intermittent fasting, non-alcoholic fatty liver disease, 5:2 diet, time-restricted feeding, alternate-day fasting, hepatic steatosis, liver stiffness, controlled attenuation parameter, weight loss, insulin resistance, anthropometric measures
- MeSH terms
- Network Meta-Analysis, Intermittent Fasting, Fatty Liver, Humans, Insulin Resistance, Cholesterol, LDL, Weight Loss, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1097/meg.0000000000002715
- The paper
- Abuelazm, M. T., Mohamed, I., Naeem, A., Khlidj, Y., Tanashat, M., Katamesh, B. E., Abusuilik, H., Altobaishat, O., Abdelnabi, M., & Abdelazeem, B. (2024). Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/meg.0000000000002715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.